@article{article, title  = {{A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2022}},

 month = {{2}},

 author = {{Powles T and Drakaki A and Teoh JY-C and Grande E and Fontes-Sousa M and Porta C and Wu E and Goluboff ET and Ho S and Hois S and Gupta AK et al}},

 doi = {{10.1200/jco.2022.40.6_suppl.tps579}},

 volume = {{40}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{TPS579-TPS579}},

 note = {{Accessed on 2024/12/22}}}